Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: SIX Swiss Ex
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ATLN:VX

114.100 CHF 0.300 0.26%

As of 11:43:59 ET on 02/27/2015.

Snapshot for Actelion Ltd (ATLN)

Open: 114.100 Day's Range: 113.400 - 114.700 Volume: 438,979
Previous Close: 114.400 52wk Range: 79.458 - 125.100 1-Yr Rtn: +24.07%

Stock Chart for ATLN

No chart data available.
  • ATLN:VX 114.100
  • 1D
  • 1M
  • 1Y
114.400
Interactive ATLN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ATLN

Current P/E Ratio (ttm) 21.3670
Estimated P/E(12/2015) 21.6344
Relative P/E vs. SMI 1.1411
Earnings Per Share (CHF) (ttm) 5.3400
Est. EPS (CHF) (12/2015) 5.2740
Est. PEG Ratio 1.7682
Market Cap (M CHF) 13,022.05
Shares Outstanding (M) 114.13
30 Day Average Volume 667,829
Price/Book (mrq) 6.9678
Price/Sale (ttm) 6.4865
Dividend Indicated Gross Yield 1.14%
Cash Dividend (CHF) 1.3000
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/21/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ATLN

  • Revenue
  • Net Income (M/CHF)
  • Profit Margin (%)

Company Profile & Key Executives for ATLN

Actelion Ltd. is a pharmaceutical company that develops and markets synthetic small-molecule drugs against diseases related to the endothelium. The Company's drugs, Veletri and Tracleer, are used in the treatment of heart and pulmonary conditions.

Jean-Paul ClozelCEO/Co-FounderAndre C MullerExec VP/CFO
Otto SchwarzExec VP/COOGuy BraunsteinExec VP/Head:Clinical Dev
More Company Profile & Key Executives for ATLN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil